Maggie L. Shaw

Recent research shows that in the setting of cocaine use among patients with heart failure (HF), those who are classified as obese had better clinical outcomes compared with patients with HF who do not have obesity.

The ASPC 2023 Congress on CVD Prevention will take place in Arlington, Texas, from July 21-23, and in this interview, President-Elect Michael Shapiro, DO, FASPC, runs down what attendees should look most forward to this year.

Outcomes in this new analysis were compared among children aged 6 to 11 years, all of whom had severe atopic dermatitis and were randomized to treatment with dupilumab or placebo for 16 weeks.

The current literature is lacking on outcomes among patients with comorbid chronic rhinosinusitis (CRS) and immunoglobulin deficiencies, especially for those who must use surgery to manage their CRS.

With this study, investigators hoped to advance their understanding of cellulitis-mimicking reactions among patients currently receiving chemotherapy.

Few validated measures exist to quantify sleep disturbance among patients who have the chronic inflammatory skin condition prurigo nodularis.

This new study compared heart failure–related outcomes between adults patients randomly assigned 1:1 by carpal tunnel syndrome status, with the principal outcome being a diagnosis of new-onset heart failure.

This newest analysis on atopic diseases compared outcomes between persons considered to be sexually diverse (lesbian, gay, or bisexual) and heterosexual individuals.

The study investigated event rates for several outcomes in the year following a first hospitalization for heart failure (HF), including implementation of guideline-directed medical therapy (GDMT).

Data included in this analysis are from the Respiratory Health in Northern Europe study, and they include asthma status, asthma-like symptoms, and other respiratory symptoms.

Outcomes of concern for this retrospective study were eosinophilic esophagitis (EOE) mucosal biopsies, EoE diagnosis, proton pump inhibitor initiation, and recommendations being followed for repeat esophagogastroduodenoscopy.

Judite Blanc, PhD, University of Miami Miller School of Medicine, discusses how total sleep needs vary among ages and the consequences of these changing hourly totals.

A new study investigated the potential impact of remote monitoring of heart failure with reduced ejection fraction (HFrEF) on care use and costs.

In this interview from SLEEP 2023, Andrew McHill, PhD, of Oregon Health and Science University (OHSU), explains the importance of individualizing sleep hygiene recommendations.

In this interview from SLEEP 2023, Dayna Johnson, PhD, MPH, MSW, MS, addresses the various pathways through which cardiovascular health is adversely affected by suboptimal sleep health.

Investigators wanted to answer the question, “Is incident myocardial infarction associated with cognitive function changes compared with pre-MI cognition trajectories?”

This international study looked at educational outcomes among adolescents with eczema as influenced by their quality of life living with the chronic inflammatory skin condition.

Investigators evaluated long-term outcomes among individuals who have eosinophilic esophagitis (EoE) and initiated first-line treatment with a food elimination diet after experiencing remission following stoppage of proton pump inhibitor monotherapy.

In this interview with The American Journal of Managed Care®, Symielle A. Gaston, PhD, MPH, of the National Institute of Environmental Health Sciences (NIEHS) of the National Institutes of Health, explores the relationship between sleep health and outcomes disparities among patients of various races and ethnicities.

Targeting insomnia with cognitive behavior therapy is almost like a frontline therapy, because by doing so, you’re able to improve a whole host of other symptoms that would coexist with insomnia, explained Sheila Garland, PhD, MSc, Memorial University in Newfoundland, Canada.

Research is finding that there is an intricate connection between sleep and inflammation, such that lack of sleep can increase inflammation, noted Andrew McHill, PhD, an assistant professor at Oregon Health and Science University.

Dayna Johnson, PhD, MPH, MSW, MS, the Rollins School of Public Health at Emory University, discusses principal findings from the analysis of a 35-day sleep intervention study that utilized a mobile mindfulness app to manage stress and anxiety combined with healthy sleep practices.

It’s important to consider the social context, the social ecology, and the family environment when investigating behavioral sleep problems among children and adults, noted Arielle Williamson, PhD, DBSM, Children's Hospital of Philadelphia and the University of Pennsylvania Perelman School of Medicine.

Judite Blanc, PhD, is lead author on the abstract, “Social Determinants of Sleep Disorders Among Multiethnic Americans in the NIH All of Us Research Program,” which was presented today at SLEEP 2023.

There are recent reports of a potential connection between atopic dermatitis in infants and young children and early exposure to antibiotics and laxatives; however, the totality of the evidence on this link remains lacking.

In this preview interview for SLEEP 2023, Rebecca Spencer, PhD, chair of the Associated Professional Sleep Societies Program Committee, highlights how bringing patients and clinicians together can inspire new ideas in sleep medicine.

This is the first study to investigate a potential connection between anthracycline chemotherapy and risk of heart failure (HF) in young adult cancer survivors.

Mitzi Joi Williams, MD, FAAN, medical director and CEO of Joi Life Wellness Neurology Clinic, discusses how underrepresentation of minority population patients in clinical trials became an issue and how education and raising awareness can begin to remedy it.

With surveys demonstrating that care disparities in atopic dermatitis (AD) may exist among pediatric patients with the chronic skin condition, investigators set out to determine AD’s prevalence by sociodemographic subgroup.

The LIBERTY-PN PRIME and PRIME2 trials investigated itch response to dupilumab among patients who have prurigo nodularis.